<DOC>
	<DOCNO>NCT00780676</DOCNO>
	<brief_summary>The goal clinical research study learn researcher use genetic test predict may benefit treatment SprycelTM ( dasatinib ) selumetinib ( AZD6244 ) .</brief_summary>
	<brief_title>Personalized Treatment Selection Metastatic Breast Cancer</brief_title>
	<detailed_description>The Study Drug : Dasatinib block several different enzyme call protein kinases found cancer cell . These enzyme important cancer cell growth . Blocking kinase may stop slow cancer growth . AZD6244 design block growth cancer cell interfere specific target molecule need tumor growth , rather simply interfere rapidly divide cell ( like traditional chemotherapy ) . Study Drug Administration : If find eligible take part study , take either dasatinib AZD6244 . The drug take decide doctor base finding tumor biopsy . - If take dasatinib , take 2 dasatinib tablet mouth every day . The dasatinib tablet need swallow whole take without meal . - If take AZD6244 , take 3 tablet mouth twice every day . The AZD6244 tablet need take 8 ounce water empty stomach ( 1 hour 2 hour meal ) 12 hour apart . If side effect , study doctor may decrease dose may stop receive study drug 21 day . While receive treatment dasatinib AZD6244 , may receive anti-cancer treatment chemotherapy hormonal therapy . If receive treatment bisphosphonate give vein ( Aredia Zometa ) , able receive drug first 8 week study . This do order avoid low calcium level blood . You may able continue receive study drug first 8 week . Study Visits : Every 4 week study , complete physical exam . Blood ( 3-4 teaspoon ) draw routine test . - If take dasatinib , Week 4 , ECG . - If take AZD6244 , Week 8 , experience heart-related side effect suggestive cardiac problem , ECHO multiple gate acquisition scan ( MUGA ) . Every 8 week , scan ( MRIs , CTs , bone scan ) x-ray perform screen repeat . If experience visual disturbance receive AZD6244 , eye exam . Length Study : You may continue take study drug daily long benefit . You take study disease get bad intolerable side effect occur . End-of-Study Visit : If take study side effect , CT scan x-rays check status disease . This investigational study . Dasatinib FDA approve treat chronic myeloid leukemia . It yet FDA approve treatment patient breast cancer . At time , use dasatinib breast cancer patient investigational . AZD6244 FDA approve commercially available . Its use study investigational . The test use find receive treatment dasatinib AZD6244 also investigational . Up 769 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . ( Turnstile One Applies inclusion criterion 1 4 ) : Histologically confirm breast cancer evidence metastatic disease biopsied acceptable risk . Patients must agree mandatory fine needle aspiration cancer response marker determination . Patient must positive gene expression profile . Positive gene expression signature obtain separately trial LAB110337 also acceptable eligibility . 2 . Patients must measurable evaluable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . 3 . Subject , age &gt; 18 year ( safety efficacy dasatinib appropriate dose establish child ) . 4 . Signed write informed consent include HIPAA form accord institutional guideline . 5 . ( Turnstile Two Applies Only Inclusion Criteria 5 17 ) Therapy Dasatinib Patient must positive gene expression profile . Positive gene expression obtain separately trial LAB110337 also acceptable eligibility . 6 . Performance status Zubrod scale 02 ( Appendix B ) within 8 day start therapy . 7 . Full physical examination history include documentation weight , height , vital sign within 8 day start therapy . 8 . Patients may receive number previous therapy metastatic breast cancer . Patients must receive , contraindication , decline treatment anthracycline taxane ( Herceptin HER2 positive ) either adjuvant metastatic setting . 9 . Adequate organ function assess within 14 day study therapy , define : ( ) Total bilirubin &lt; /= 2.0 time institutional Upper Limit Normal ( ULN ) ; ( b ) Hepatic enzyme ( AST , ALT ) &lt; /= 2.5 time institutional ULN ; ( c ) Serum Na , K+ , Mg2+ , Phosphate Ca2+ &gt; /= low limit normal ( LLN ) ; ( ) Serum Creatinine &lt; 1.5 time institutional ULN ; ( e ) Hemoglobin , Neutrophil count , Platelets , PT , PTT Grade 01 . 10 . A baseline EKG within 14 day start therapy , QTc interval &gt; 460 msec woman , &gt; 450 men . 11 . Ability take oral medication ( dasatinib must swallow whole ) . 12 . Patient must agree discontinue St. Johns Wort receive dasatinib therapy previously take . 13 . Patient must agree IV bisphosphonate therapy withhold first 8 week dasatinib therapy due risk hypocalcemia . ( After need Ca2+ supplementation assess level document &gt; LLN , subject prior bisphosphonate may restart caution investigator 's discretion ) . 14 . Females childbearing potential must negative serum pregnancy test within 7 day start therapy . 15 . Persons reproductive potential must agree use utilize barrier method contraception throughout treatment least 4 week study drug stop . 16 . Concurrent medication must assess , patient must agree discontinue restrict medication within 7 day start therapy . 17 . Stable brain metastasis least 3 month 1 . ( Only turnstile II applies Exclusion Criteria ) : Known allergy study drug . 2 . Concurrent medical condition may increase risk toxicity , include : ( ) pleural pericardial effusion grade ; ( b ) uncontrolled angina , congestive heart failure MI within ( 6 month ) ; ( c ) history congenital long QT syndrome prolong QTc interval preentry electrocardiogram &gt; 460 msec woman &gt; 450 msec . men ; ( ) history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) ; continue excl # 3 3 . Continued exclusion # 2 : ( e ) subject hypokalemia hypomagnesemia correct prior dasatinib administration ; ( f ) history significant bleeding disorder unrelated cancer , include diagnose congenital bleeding disorder ( e.g. , von Willebrand 's disease ) acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) ; ( g ) ongoing recent ( 3 month ) significant gastrointestinal bleeding 4 . Concomitant medication follow drug consider exclusion unless discontinue 7 day prior start dasatinib : ( ) Category I drug prolong QT interval generally accept risk cause Torsades de Pointes include : quinidine , procainamide , disopyramide , amiodarone , sotalol , ibutilide , dofetilide , erythromycin , clarithromycin , chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide , cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone . Cont . exclusion # 5 5 . Continued exclusion criterion # 4 : halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine . 6 . CYP3A4 inhibitor . Dasatinib primarily metabolize CYP3A4 enzyme . Therefore , potent inhibitor CYP3A4 may increase dasatinib plasma concentration : ( ) ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir ; ( ii ) telithromycin ; ( iii ) subject advise consume substantial quantity grapefruit juice . 7 . Medications durably inhibit platelet function inhibit anticoagulation . Medications directly durably inhibit platelet function coagulation include : ( ) aspirin aspirincontaining combination , clopidogrel , dipyridamole , tirofiban , dipyridamole , epoprostenol , eptifibatide , cilostazol , abciximab , ticlopidine , cilostazol ; ( ii ) warfarin , heparin/low molecular weight heparin [ e.g. , danaparoid , dalteparin , tinzaparin , enoxaparin ] . Exceptions : lowdose warfarin prophylaxis prevent catheter thrombosis , heparin flush IV line allow . 8 . Women unwilling unable use barrier method contraception avoid pregnancy entire study period least 4 week cessation study drug , positive pregnancy test baseline , pregnant breastfeeding . Prior study enrollment , woman childbearing potential must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy . 9 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness . 10 . Exclusion Selumetinib therapy include Uncontrolled hypertension ( BP &gt; /=150/95 mmHg ) , Heart failure ( NYHA &gt; /= Class II ) , prior current cardiomyopathy ( LVEF &lt; /= 50 % ) , Atrial fibrillation ( heart rate &gt; 100 bpm ) , Unstable ischaemic heart disease ( MI within 6 month prior , angina require use nitrate weekly ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Dasatinib</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Sprycel</keyword>
	<keyword>BMS-354825</keyword>
	<keyword>Genetic testing</keyword>
	<keyword>AZD6244</keyword>
	<keyword>Selumetinib</keyword>
</DOC>